Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation
Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Marcella Mottolese, Michèle Milella(National Cancer Institute), Giulio Metro(University of Perugia), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Isabella Sperduti(San Gallicano Hospital), Federica Tomao(Sapienza University of Rome), Michelangelo Russillo(National Cancer Institute), Alain Gelibter(Policlinico Umberto I), Elisa Melucci, Paola Papaldo(Cancer Institute (WIA)), Paolo Carlini(National Cancer Institute)
Cited by 37
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
PTEN: Multiple Functions in Human Malignant Tumors
|Frontiers in Oncology|2015|460